Completed PHASE2 INTERVENTIONAL NCT00013598

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Fatty Liver Nonalcoholic Steatohepatitis

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Mar 31, 2001 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00013598, this PHASE2 trial focuses on Fatty Liver and Nonalcoholic Steatohepatitis and remains completed. Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it has been updated 5 times since 2001, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States